Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

(2011) Sang Kyun Sohn et al.   LEUKEMIA & LYMPHOMA

Mechanisms of resistance to BCR–ABL kinase inhibitors

(2011) Joana M. Diamond et al.   LEUKEMIA & LYMPHOMA

CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity

(2010) Henrik Gréen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

(2010) Naoto Takahashi et al.   JOURNAL OF HUMAN GENETICS

Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2

(2009) Yuko Tanihara et al.   BIOCHEMICAL PHARMACOLOGY

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

(2009) J E Cortes et al.   LEUKEMIA

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

(2009) Elias Jabbour et al.   MAYO CLINIC PROCEEDINGS

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

CYP450 pharmacogenetics for personalizing cancer therapy

(2008) Ron H.N. van Schaik   DRUG RESISTANCE UPDATES